Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach

Source
Pharmacoeconomics - ISSN 1170-7690-27:1 (2009) p. 69-80

Essays on economic evaluation in health economics bridging the gap with health econometrics: applications in ADHD, schizophrenia and stents

Source
Antwerpen, 2009,244 p.

Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective

Source
Pharmacoeconomics - ISSN 1170-7690-27:4 (2009) p. 313-327
Author(s)

Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach

Source
Antwerp, UA, 2007,29 p.

Drug eluting stents in Belgium: health technology assessment

Source
Brussel, Federaal Kenniscentrum voor de Gezondheidszorg, 2007,199 p.
Author(s)

Kinderen met ADHD in Vlaanderen: profiel van zorgconsumptie, schoolresultaten en impact op het gezin

Source
Tijdschrift voor geneeskunde - ISSN 0371-683X-63:11 (2007) p. 525-531

Order bias in estimates of willingness to pay for drugs to treat attention-deficit hyperactivity disorder

Source
The European journal of health economics - ISSN 1618-7598-6 (2005) p. 146-151

Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder: a contingent valuation study among students

Source
Antwerp, UA, 2002,19 p.